<DOC>
	<DOCNO>NCT00018967</DOCNO>
	<brief_summary>RATIONALE : Chemoprotective drug carboxypeptidase-G2 may protect normal cell toxic effect chemotherapy . PURPOSE : Clinical trial study effectiveness carboxypeptidase-G2 treat nervous system toxic effect patient give accidental overdose intrathecal methotrexate .</brief_summary>
	<brief_title>Carboxypeptidase-G2 Treating Nervous System Toxic Effects Patients Given Overdose Intrathecal Methotrexate</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness carboxypeptidase-G2 rescue patient develop life threaten methotrexate ( MTX ) neurotoxicity follow accidental intrathecal MTX overdose . - Study CSF pharmacokinetics MTX follow rescue . OUTLINE : Patients undergo lumbar puncture soon possible methotrexate overdose remove methotrexate receive single dose carboxypeptidase-G2 intrathecally 5 minute . Patients follow least 1 month . PROJECTED ACCRUAL : A maximum 10 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients receive intrathecal overdose methotrexate 100 mg PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior anaphylactic reaction carboxypeptidaseG2 administration PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Concurrent therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>neurotoxicity</keyword>
</DOC>